日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review

强直性脊柱炎发病10年内患者低骨密度发生率高：一项系统评价

期刊:Clinical Rheumatology
影响因子:2.8
doi:10.1007/s10067-012-2018-0
van der Weijden, M A C; Claushuis, T A M; Nazari, T; Lems, W F; Dijkmans, B A C; van der Horst-Bruinsma, I E
强直性脊柱炎
免疫/内分泌
发表日期：2012
文献求助 收藏

Efficacy of serology driven "test and treat strategy" for eradication of H. pylori in patients with rheumatic disease in the Netherlands

荷兰风湿病患者中，血清学驱动的“检测和治疗策略”根除幽门螺杆菌的疗效

期刊:European Journal of Clinical Microbiology & Infectious Diseases
影响因子:3
doi:10.1007/s10096-011-1174-5
de Leest, H T J I; Steen, K S S; Lems, W F; van de Laar, M A F J; Huisman, A M; Kadir, S W; Houben, H H M L; Kostense, P J; Kuipers, E J; Dijkmans, B A C; Debets-Ossenkopp, Y J
发表日期：2011
文献求助 收藏

Low bone mineral density is related to male gender and decreased functional capacity in early spondylarthropathies

骨密度低与男性性别和早期脊柱关节病患者功能能力下降有关。

期刊:Clinical Rheumatology
影响因子:2.8
doi:10.1007/s10067-010-1538-8
van der Weijden, M A C; van Denderen, J C; Lems, W F; Heymans, M W; Dijkmans, B A C; van der Horst-Bruinsma, I E
发表日期：2011
文献求助 收藏

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

阿达木单抗治疗强直性脊柱炎的疗效可持续长达2年：ATLAS试验的长期结果

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/ard.2007.087270
van der Heijde, D; Schiff, M H; Sieper, J; Kivitz, A J; Wong, R L; Kupper, H; Dijkmans, B A C; Mease, P J; Davis, J C Jr
强直性脊柱炎
免疫/内分泌
发表日期：2009
文献求助 收藏

A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue

一项前瞻性、随机、安慰剂对照研究，旨在识别与银屑病关节炎积极治疗相关的生物标志物：阿达木单抗治疗对滑膜组织的影响

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/ard.2008.091389
van Kuijk, A W R; Gerlag, D M; Vos, K; Wolbink, G; de Groot, M; de Rie, M A; Zwinderman, A H; Dijkmans, B A C; Tak, P P
关节炎
银屑病
发表日期：2009
文献求助 收藏

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

来自六种免疫介导炎症性疾病全球临床试验的阿达木单抗安全性和死亡率

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/ard.2008.102103
Burmester, G R; Mease, P; Dijkmans, B A C; Gordon, K; Lovell, D; Panaccione, R; Perez, J; Pangan, A L
炎症/感染
炎症
免疫/内分泌
发表日期：2009
文献求助 收藏

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium

类风湿性关节炎患者对英夫利昔单抗的临床反应部分取决于治疗前滑膜中肿瘤坏死因子α的表达。

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/ard.2007.080440
Wijbrandts, C A; Dijkgraaf, M G W; Kraan, M C; Vinkenoog, M; Smeets, T J; Dinant, H; Vos, K; Lems, W F; Wolbink, G J; Sijpkens, D; Dijkmans, B A C; Tak, P P
关节炎
肿瘤
肿瘤免疫
发表日期：2008
文献求助 收藏

A 57-year-old man who developed arthritis during R-CHOP chemotherapy for non-Hodgkin lymphoma

一名57岁男性，在接受R-CHOP化疗治疗非霍奇金淋巴瘤期间出现关节炎。

期刊:Clinical Rheumatology
影响因子:2.8
doi:10.1007/s10067-007-0704-0
Swaneveld, F H; van Vugt, R M; de Boer, J P; Dijkmans, B A C; Lems, W F
CHOP
关节炎
HOP
淋巴瘤
发表日期：2008
文献求助 收藏

Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation

英夫利昔单抗治疗强直性脊柱炎疗效不佳与抗体形成有关

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/ard.2006.057745
de Vries, M K; Wolbink, G J; Stapel, S O; de Groot, E R; Dijkmans, B A C; Aarden, L A; van der Horst-Bruinsma, I E
强直性脊柱炎
免疫/内分泌
发表日期：2007
文献求助 收藏

Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis

脂质与炎症：对后来患上类风湿性关节炎的献血者进行血脂谱的连续测量

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/ard.2006.051672
van Halm, V P; Nielen, M M J; Nurmohamed, M T; van Schaardenburg, D; Reesink, H W; Voskuyl, A E; Twisk, J W R; van de Stadt, R J; de Koning, M H M T; Habibuw, M R; van der Horst-Bruinsma, I E; Dijkmans, B A C
炎症/感染
关节炎
炎症
发表日期：2007
文献求助 收藏